Study of Investigational Medication Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (TTP)

What we are studying

The main purpose of this study is to see how well people tolerate receiving the study drug (caplacizumab) compared with people who receive placebo (a product that does not contain any active ingredients and looks identical to the study drug). This will allow a comparison of the effects produced by the study drug. In addition, the study will see if caplacizumab helps to prevent a worsening of your TTP episode and helps to restore normal levels of platelets in your blood.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Adult male or female age 18 years or older
  • Clinical diagnosis of acquired TTP
  • Require daily plasma exchange treatment

What is involved

  • Daily treatment with study drug / placebo on days when plasma exchange is received and 30 days post daily plasma exchange
  • Blood tests


You will not receive any payment for your participation in the study. You may be reimbursed for transportation to and from the site expenses for participation in this study.

Contact Information

Study Coordinator
Scarlett Hutchens, RN, BSN
Principal Investigator
Andrew Farland, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.